Semi-Annual Consolidated Balance Sheet

K Pharma,Inc. - Filing #7344418

Concept As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Semi-annual consolidated balance sheet
Balance sheet
Assets
Current assets
Cash and deposits
3,266,408,000 JPY
1,336,847,000 JPY
Other
391,000 JPY
1,477,000 JPY
Current assets
3,308,968,000 JPY
1,370,928,000 JPY
Non-current assets
Property, plant and equipment
Construction in progress
JPY
8,350,000 JPY
Investments and other assets
4,934,000 JPY
3,638,000 JPY
Investments and other assets
Non-current assets
4,934,000 JPY
3,638,000 JPY
Assets
3,313,902,000 JPY
1,374,566,000 JPY
Liabilities
Current liabilities
Income taxes payable
69,583,000 JPY
1,900,000 JPY
Other
59,714,000 JPY
JPY
Current liabilities
178,480,000 JPY
33,683,000 JPY
Non-current liabilities
Asset retirement obligations
30,654,000 JPY
4,619,000 JPY
Non-current liabilities
30,654,000 JPY
4,619,000 JPY
Liabilities
209,134,000 JPY
38,302,000 JPY
Net assets
Shareholders' equity
Share capital
854,087,000 JPY
100,000,000 JPY
Capital surplus
3,003,337,000 JPY
2,249,250,000 JPY
Retained earnings
-752,656,000 JPY
-1,012,986,000 JPY
Shareholders' equity
3,104,768,000 JPY
1,336,263,000 JPY
Net assets
974,700,000 JPY
854,087,000 JPY
3,104,768,000 JPY
-752,656,000 JPY
3,104,768,000 JPY
2,028,637,000 JPY
3,003,337,000 JPY
-752,656,000 JPY
-1,012,986,000 JPY
1,336,263,000 JPY
1,274,550,000 JPY
2,249,250,000 JPY
1,336,263,000 JPY
100,000,000 JPY
-1,012,986,000 JPY
974,700,000 JPY
-620,559,000 JPY
178,891,000 JPY
100,000,000 JPY
-620,559,000 JPY
199,800,000 JPY
499,650,000 JPY
699,450,000 JPY
178,891,000 JPY
Liabilities and net assets
3,313,902,000 JPY
1,374,566,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.